{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-22-000103","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.123638+00:00","generated_at":"2026-06-22T08:18:46.320687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q3 rev $213.7M (+12.4%); cuts FY22 guide to $840-845M on Flash delay, FX headwind","bullets":["Revenue $213.7M, +12.4% YoY (+15.1% constant currency); vascular +17%, neuro +6.7%.","GAAP operating income $5.4M vs $8.8M prior year; non-GAAP op income $7.8M.","FY2022 revenue guidance reduced to $840-845M; cites Lightning Flash launch delay to Q1 2023 and $4-6M FX headwind.","Expects to reach $1B revenue in 2023.","Gross margin 63.3% vs 63.1% prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-22-000103","json":"https://secwatch.observer/filing/0001321732-22-000103.json","markdown":"https://secwatch.observer/filing/0001321732-22-000103.md","text":"https://secwatch.observer/filing/0001321732-22-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173222000103/0001321732-22-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173222000103/pen-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:18:46.320687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f6ce95be739575c4cfddaa3659cc8f55b9de52e","claim":"Penumbra Inc updated its 2022 guidance (lowered).","evidence_excerpt":"The Company now expects 2022 total revenue to be in the range of $840 million to $845 million, which reflects growth of 12-13% on a reported basis and 15-16% in constant currency compared to 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173222000103/0001321732-22-000103-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d0ef3350334fcfc42bac4753e37df9e21279ab79","claim":"Penumbra Inc reported the third quarter ended September 30, 2022 results: revenue $213.7 million. Guidance lowered.","evidence_excerpt":"Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2022. • Revenue of $213.7 million in the third quarter of 2022, an increase of 12.4%, or 15.1% in constant currency 1 , compared to the third quarter of 2021. Third Quarter 2022 Financial Results Total revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173222000103/0001321732-22-000103-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$213.7 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}